menu
    • menu
    [{"orgOrder":0,"company":"Sudo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SUDO-550","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Sudo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sudo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sudo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sudo Biosciences","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"SUDO-550","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Sudo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sudo Biosciences \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sudo Biosciences \/ Enavate Sciences"},{"orgOrder":0,"company":"Sudo Biosciences","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"SUDO-550","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Sudo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sudo Biosciences \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sudo Biosciences \/ Enavate Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Sudo Biosciences

    Menu

    Sudo Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sudo Biosciences

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Sudo Biosciences

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SUDO-550

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sudo Biosciences Begins Phase 1 Trial for TYK2 Inhibitor SUDO-550 in the Brain

                            Details : SUDO-550 is a novel brain-penetrant allosteric TYK2 inhibitor, being investigated for the treatment of neuroinflammatory diseases.

                            Product Name : SUDO-550

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : SUDO-550

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sudo Biosciences

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Sudo Biosciences

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SUDO-550

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Enavate Sciences

                            Deal Size : $147.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Sudo Biosciences Closes Upsized Series B Financing Totaling $147M

                            Details : The proceeds will advance brain-penetrant SUDO-550 in multiple sclerosis and SUDO-286, a topical TYK2 candidate for psoriasis, into clinical trials as first and best-in-class candidates.

                            Product Name : SUDO-550

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 13, 2024

                            Lead Product(s) : SUDO-550

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Enavate Sciences

                            Deal Size : $147.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sudo Biosciences

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Sudo Biosciences

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SUDO-550

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Enavate Sciences

                            Deal Size : $116.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in-Class TYK2 Therapeutics Programs...

                            Details : The net proceeds will advance potential first and best-in-class brain-penetrant TYK2 candidate, SUDO-550, in multiple sclerosis and potential first- and best-in-class topical dermal TYK2 candidate, SUDO-286, in psoriasis into the clinic.

                            Product Name : SUDO-550

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 20, 2023

                            Lead Product(s) : SUDO-550

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Enavate Sciences

                            Deal Size : $116.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth